Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | BCHE | P06276 | 2/20 | 0.34 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.33 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13665385 | 1.00 | MAOA (0.34) | MAOAMAOBBCHEHSD17B3NISCH | |
| SCHEMBL264532 | 1.00 | MAOA (0.34) | MAOAMAOBBCHEHSD17B3NISCH | |
| SCHEMBL10267838 | 0.81 | MAOA (0.37) | MAOAMAOBHSD17B3 | |
| SCHEMBL26320515 | 0.77 | MAOA (0.34) | MAOAMAOBBCHENISCH | |
| SCHEMBL17725195 | 0.77 | BCHE (0.34) | MAOAMAOBBCHENISCH | |
| SCHEMBL17537081 | 0.77 | GPR84 (0.40) | MAOAMAOBBCHEHSD17B3NISCH | |
| SCHEMBL3807251 | 0.77 | MAOA (0.34) | MAOAMAOBBCHENISCH | |
| SCHEMBL12875556 | 0.77 | BCHE (0.42) | MAOAMAOBBCHEHSD17B3 | |
| SCHEMBL11509206 | 0.77 | BCHE (0.42) | MAOAMAOBBCHEHSD17B3 | |
| SCHEMBL29868583 | 0.77 | BCHE (0.33) | MAOAMAOBBCHEHSD17B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2016-08-04 | — | — | US | disclosed |
| EP-3042910-A2 | 2'-SPIRO-NUCLEOSIDES FOR USE IN THE THERAPY OF HEPATITIS C | Gilead Pharmasset LLC (US) | 2016-07-13 | — | — | EP | disclosed |
| WO-2015038596-A1 | NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2015-03-19 | — | — | WO | disclosed |
| US-8742094-B2 | Method for the solid phase-based production of phosphate-bridged nucleoside conjugates | UNIVERSITAET HAMBURG (DE) | 2014-06-03 | — | — | US | disclosed |
| US-8629265-B2 | Method for producing phosphate-bridged nucleoside conjugates | UNIVERSITAET HAMBURG (DE) | 2014-01-14 | — | — | US | disclosed |
| US-8440813-B2 | Antiviral nucleoside analogs | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20120213735-A1 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| WO-2012075140-A1 | COMPOUNDS | PHARMASSET, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| US-20120142617-A1 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120116067-A1 | METHOD FOR THE SOLID PHASE-BASED PRODUCTION OF PHOSPHATE-BRIDGED NUCLEOSIDE CONJUGATES | UNIVERSITAET HAMBURG (DE) | 2012-05-10 | — | — | US | disclosed |
| US-8163703-B2 | Hepatitis C therapies | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8133870-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-7994139-B2 | Antiviral therapeutic agents | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-20110137023-A1 | METHOD FOR PRODUCING PHOSPHATE-BRIDGED NUCLEOSIDE CONJUGATES | UNIVERSITAET HAMBURG (DE) | 2011-06-09 | — | — | US | disclosed |
| US-20100143300-A1 | HEPATITIS C THERAPIES | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2010-06-10 | — | — | US | disclosed |
| US-20100015094-A1 | ANTIVIRAL NUCLEOSIDE ANALOGS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2010-01-21 | — | — | US | disclosed |
| US-20090227524-A1 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-7514410-B2 | Hepatitis C therapies | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-7429571-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, NTPCR, TYMP | MAOA 3889/4885MAOB 3684/4885BCHE 2791/4885 |
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | DPYD, TYMP, TYMS | MAOA 3118/4885MAOB 2518/4885BCHE 4567/4885 |
| US-20110137023-A1 | METHOD FOR PRODUCING PHOSPHATE-BRIDGED NUCLEOSIDE CONJUGATES | TYMP, PNP, NUDT1 | MAOA 1342/4885MAOB 880/4885BCHE 1720/4885 |
| US-20120142617-A1 | ANTIVIRAL THERAPEUTIC AGENTS | EIF2AK2, ZC3HAV1, MAVS | MAOA 3580/4885MAOB 3872/4885BCHE 4228/4885 |
| US-20100015094-A1 | ANTIVIRAL NUCLEOSIDE ANALOGS | TYMP, SAMHD1, TYMS | MAOA 2725/4885MAOB 2704/4885BCHE 3791/4885 |
| US-20120116067-A1 | METHOD FOR THE SOLID PHASE-BASED PRODUCTION OF PHOSPHATE-BRIDGED NUCLEOSIDE CONJUGATES | PNP, TYMP, DPYD | MAOA 1236/4885MAOB 914/4885BCHE 1310/4885 |
| US-20090227524-A1 | ANTIVIRAL THERAPEUTIC AGENTS | EIF2AK2, ZC3HAV1, MAVS | MAOA 3580/4885MAOB 3872/4885BCHE 4228/4885 |
| US-20120213735-A1 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | DPYD, TYMP, TYMS | MAOA 3118/4885MAOB 2518/4885BCHE 4567/4885 |
| US-20100143300-A1 | HEPATITIS C THERAPIES | HAVCR2, FABP1, LIPC | MAOA 3848/4885MAOB 3174/4885BCHE 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.